STAINES-UPON-THAMES, United
Kingdom, Oct. 4, 2017
/PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading
specialty pharmaceutical company, is holding its investor briefing
today in New York City with
presentations by Mallinckrodt executives Mark Trudeau, President and Chief Executive
Officer; Ron Lloyd, Executive Vice
President and President, Hospital Therapies; Hugh O'Neill, Executive Vice President and
President, Autoimmune and Rare Diseases; and Steve Romano, M.D., Executive Vice President and
Chief Scientific Officer.
The event will highlight how Mallinckrodt's ongoing portfolio transformation has
enhanced financial strength and broadened future opportunities,
providing long-term value for patients and shareholders.
At the briefing, members of the company's management team and
medical experts, both internal and external, will share insights on
a number of topics, including:
- Development pipeline highlights:
-
- Updates on the company's broad spectrum of near- and
longer-term developmental programs for inline and investigational
assets, including clinical and health economic data
- Aggregate net sales expectations for near-term development
programs, the sum of which is expected to exceed $675 million at peak, with total pipeline
expected to exceed net sales of $1
billion at peak
- Pipeline expected to contribute >20% of total growth long
term
- Four product launches expected over next three years
- Scientific poster presentations on key development products;
and
- Product demonstrations of the INOMAX and Therakos
platforms.
Poster presentations for the Investor Briefing can be found at
the company's Investor Relations website at
http://www.mallinckrodt.com/investors/presentations. The event
general session presentations will be posted throughout the
day.
Those unable to attend the briefing in person can view a live
webcast of the presentations and Q&A session at Mallinckrodt's Investor Relations website, linked
here, beginning at 11:45 a.m. Eastern
Time, with the general session expected to conclude at
approximately 5:15 p.m. The poster
session will not be available via webcast.
ABOUT MALLINCKRODT
Mallinckrodt is a global business
that develops, manufactures, markets and distributes specialty
pharmaceutical products and therapies. Areas of focus include
autoimmune and rare diseases in specialty areas like neurology,
rheumatology, nephrology, pulmonology and ophthalmology;
immunotherapy and neonatal respiratory critical care therapies;
analgesics and hemostasis products. The company's core strengths
include the acquisition and management of highly regulated raw
materials and specialized chemistry, formulation and manufacturing
capabilities. The company's Specialty Brands segment includes
branded medicines and its Specialty Generics segment includes
specialty generic drugs, active pharmaceutical ingredients and
external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
Cautionary Statements Related to Forward-Looking
Statements
Statements in this document that are not strictly
historical, including statements regarding future financial
condition and operating results, economic, business, competitive
and/or regulatory factors affecting Mallinckrodt's businesses and any other statements
regarding events or developments that we believe or anticipate will
or may occur in the future, may be "forward-looking" statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, and involve a number of risks and uncertainties.
There are a number of important factors that could cause actual
events to differ materially from those suggested or indicated by
such forward-looking statements and you should not place undue
reliance on any such forward-looking statements. These factors
include risks and uncertainties related to, among other things:
general economic conditions and conditions affecting the industries
in which Mallinckrodt operates; the
commercial success of Mallinckrodt's
products; Mallinckrodt's ability to
realize anticipated growth, synergies and cost savings from
transactions; conditions that could necessitate an evaluation of
Mallinckrodt's goodwill and/or
intangible assets for possible impairment; changes in laws and
regulations; Mallinckrodt's ability to
successfully integrate acquisitions of operations, technology,
products and businesses generally and to realize anticipated
growth, synergies and cost savings; Mallinckrodt's ability to successfully develop or
commercialize new products; Mallinckrodt's ability to protect intellectual
property rights; Mallinckrodt's ability
to receive procurement and production quotas granted by the U.S.
Drug Enforcement Administration; customer concentration;
Mallinckrodt's reliance on certain
individual products that are material to its financial performance;
cost containment efforts of customers, purchasing groups,
third-party payers and governmental organizations; the
reimbursement practices of a small number of public or private
insurers; pricing pressure on certain of Mallinckrodt's products due to legal changes or
changes in insurers' reimbursement practices resulting from recent
increased public scrutiny of healthcare and pharmaceutical costs;
limited clinical trial data for H.P. Acthar® Gel;
complex reporting and payment obligations under healthcare rebate
programs; Mallinckrodt's ability to
navigate price fluctuations; future changes to U.S. and foreign tax
laws; Mallinckrodt's ability to achieve
expected benefits from restructuring activities; complex
manufacturing processes; competition; product liability losses and
other litigation liability; ongoing governmental investigations;
material health, safety and environmental liabilities; retention of
key personnel; conducting business internationally; the
effectiveness of information technology infrastructure; and
cybersecurity and data leakage risks.
These and other factors are identified and described in more
detail in the "Risk Factors" sections of Mallinckrodt's Annual Report on Form 10-K for the
fiscal year ended September 30, 2016.
The forward-looking statements made herein speak only as of the
date hereof and Mallinckrodt does not
assume any obligation to update or revise any forward-looking
statement, whether as a result of new information, future events
and developments or otherwise, except as required by law.
CONTACTS
Investor
Relations
Coleman
N. Lannum, CFA
Senior Vice President, Investor Strategy & IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda
Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-plc-discusses-pipeline-transformation-company-outlook-at-investor-briefing-300530684.html
SOURCE Mallinckrodt plc